ARTICLE | Company News
OctreoPharm, Novartis deal
October 17, 2011 7:00 AM UTC
OctreoPharm exercised an option under a 2009 deal with Novartis to license exclusive, worldwide rights to develop and commercialize OPS101. The option was triggered after OctreoPharm's provided the p...